BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Reports Updated Phase 1a Data for TTX-MC138 in Advanced Solid Tumors

TransCode Therapeutics (NASDAQ: RNAZ) reported updated clinical data from its Phase 1a trial of TTX-MC138 in patients with relapsed or refractory, unresectable locally advanced or metastatic solid tumors. As of Sept. 1, 10 of 14 efficacy-evaluable patients, or 71.4%, achieved stable disease as their best overall response, while six patients were progression-free at three months […]